|
US3933961A
(en)
|
1974-12-13 |
1976-01-20 |
Pennwalt Corporation |
Tabletting spherical dental amalgam alloy
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
JP3022967B2
(ja)
|
1985-03-15 |
2000-03-21 |
アンチバイラルズ インコーポレイテッド |
立体規則性ポリヌクレオチド結合ポリマー
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US4866042A
(en)
|
1987-11-18 |
1989-09-12 |
Neuwelt Edward A |
Method for the delivery of genetic material across the blood brain barrier
|
|
US6294520B1
(en)
|
1989-03-27 |
2001-09-25 |
Albert T. Naito |
Material for passage through the blood-brain barrier
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
JPH0813274B2
(ja)
|
1990-08-13 |
1996-02-14 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
AU4684993A
(en)
|
1992-07-23 |
1994-02-14 |
Isis Pharmaceuticals, Inc. |
Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
|
|
EP0669987B1
(en)
|
1992-09-25 |
2008-08-13 |
Aventis Pharma S.A. |
Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
|
|
CN1123038A
(zh)
|
1993-05-11 |
1996-05-22 |
北卡罗来纳大学查珀尔希尔分校 |
阻止异常剪接的反义寡核苷酸及其使用方法
|
|
JP3715314B2
(ja)
|
1993-12-24 |
2005-11-09 |
ユニバーシティ オブ ウェールズ カレッジ オブ メディスン |
結節硬化症２遺伝子及びその利用
|
|
US5656612A
(en)
|
1994-05-31 |
1997-08-12 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
|
FR2727867B1
(fr)
|
1994-12-13 |
1997-01-31 |
Rhone Poulenc Rorer Sa |
Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
|
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
|
ATE267207T1
(de)
|
1996-02-14 |
2004-06-15 |
Isis Pharmaceuticals Inc |
Kohlenhydratmodifizierte luckenhafte oligonukleotide
|
|
GB9605808D0
(en)
|
1996-03-20 |
1996-05-22 |
Isis Innovation |
CFTR gene regulator
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US5955279A
(en)
|
1996-06-13 |
1999-09-21 |
Gatti; Richard A. |
Ataxia-telangiectasia: mutations in the ATM gene
|
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
US7011973B1
(en)
|
1997-06-03 |
2006-03-14 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells in vivo and uses thereof
|
|
US6963589B1
(en)
|
1997-07-03 |
2005-11-08 |
Canon Kabushiki Kaisha |
Information processing apparatus for and method of transmitting and/or receiving broadcast signal
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
GB9716231D0
(en)
|
1997-07-31 |
1997-10-08 |
Amersham Int Ltd |
Base analogues
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
AU9063398A
(en)
|
1997-09-12 |
1999-04-05 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7045610B2
(en)
|
1998-04-03 |
2006-05-16 |
Epoch Biosciences, Inc. |
Modified oligonucleotides for mismatch discrimination
|
|
AU762437B2
(en)
|
1998-08-24 |
2003-06-26 |
Medical Therapies Limited |
Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
US7071324B2
(en)
|
1998-10-13 |
2006-07-04 |
Brown University Research Foundation |
Systems and methods for sequencing by hybridization
|
|
US20030224514A1
(en)
|
2002-05-31 |
2003-12-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of PPAR-delta expression
|
|
US6436657B1
(en)
|
1998-12-18 |
2002-08-20 |
E. I. Du Pont De Nemours And Company |
Polynucleotides encoding aminomethyltransferases
|
|
CZ296576B6
(cs)
|
1999-02-12 |
2006-04-12 |
Sankyo Company Limited |
Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
CN1350542A
(zh)
|
1999-03-18 |
2002-05-22 |
埃克西库恩公司 |
木－lna类似物
|
|
JP4768132B2
(ja)
|
1999-03-24 |
2011-09-07 |
エクシコン エ／エス |
［２．２．１］ビシクロヌクレオシドの改良された製法
|
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
|
US6383752B1
(en)
|
1999-03-31 |
2002-05-07 |
Hybridon, Inc. |
Pseudo-cyclic oligonucleobases
|
|
EP1178999B1
(en)
|
1999-05-04 |
2007-03-14 |
Santaris Pharma A/S |
L-ribo-lna analogues
|
|
US6083482A
(en)
|
1999-05-11 |
2000-07-04 |
Icn Pharmaceuticals, Inc. |
Conformationally locked nucleosides and oligonucleotides
|
|
US6531591B1
(en)
|
1999-07-07 |
2003-03-11 |
Exiqon A/S |
Synthesis of stable quinone and photoreactive ketone phosphoramidite reagents for solid phase synthesis of photoreactive-oligomer conjugates
|
|
JP4151751B2
(ja)
|
1999-07-22 |
2008-09-17 |
第一三共株式会社 |
新規ビシクロヌクレオシド類縁体
|
|
US6458536B1
(en)
|
1999-07-23 |
2002-10-01 |
The Regents Of The University Of California |
Modified SSCP method using sequential electrophoresis of multiple nucleic acid segments
|
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
|
US6187586B1
(en)
|
1999-12-29 |
2001-02-13 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of AKT-3 expression
|
|
US6784291B2
(en)
|
2000-05-04 |
2004-08-31 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
|
US6809194B1
(en)
|
2000-05-10 |
2004-10-26 |
Chiron Corporation |
Akt3 inhibitors
|
|
US7553644B2
(en)
|
2000-07-13 |
2009-06-30 |
The Johns Hopkins University School Of Medicine |
Detection and treatment of polycystic kidney disease
|
|
WO2002018388A1
(fr)
|
2000-08-29 |
2002-03-07 |
Takeshi Imanishi |
Analogues de nucleosides et derives d'oligonucleotides renfermant ces analogues
|
|
NZ524894A
(en)
|
2000-09-02 |
2005-03-24 |
Gruenenthal Chemie |
Antisense oligonucleotides against VR1
|
|
JP4413493B2
(ja)
|
2000-10-04 |
2010-02-10 |
サンタリス ファーマ アー／エス |
プリンｌｎａ類似体の改善された合成方法
|
|
JP2002345489A
(ja)
|
2000-11-03 |
2002-12-03 |
Astrazeneca Ab |
化学物質
|
|
JP2004537517A
(ja)
|
2001-05-17 |
2004-12-16 |
エイブイアイ バイオファーマ， インコーポレイテッド |
ｃ−ｍｙｃアンチセンスオリゴマーを使用した、癌を処置するための併用アプローチ
|
|
AU2002328792A1
(en)
|
2001-07-12 |
2003-01-29 |
Santaris Pharma A/S |
Method for preparation of lna phosphoramidites
|
|
US7037658B2
(en)
|
2001-08-16 |
2006-05-02 |
Regents Of University Of Michigan |
Methods and compositions for detecting variant ADAMTS13 genes
|
|
AU2002334307A1
(en)
|
2001-09-04 |
2003-03-18 |
Exiqon A/S |
Novel lna compositions and uses thereof
|
|
US6936589B2
(en)
|
2001-09-28 |
2005-08-30 |
Albert T. Naito |
Parenteral delivery systems
|
|
JP2005508196A
(ja)
|
2001-11-07 |
2005-03-31 |
アプレラ コーポレイション |
核酸分析の汎用ヌクレオチド
|
|
EP1481983A4
(en)
|
2002-02-13 |
2008-04-02 |
Takeshi Imanishi |
NUCLEOSIDE ANALOGUE AND OLIGONUCLEOTIDE DERIVATIVES CONTAINING A NUCLEOTIDE ANALOGON THEREOF
|
|
JP4476802B2
(ja)
|
2002-05-08 |
2010-06-09 |
サンタリス ファーマ アー／エス |
ロックト核酸誘導体の製造
|
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
WO2004001010A2
(en)
|
2002-06-21 |
2003-12-31 |
Ptc Therapeutics, Inc. |
METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
|
|
US20040023220A1
(en)
|
2002-07-23 |
2004-02-05 |
Lawrence Greenfield |
Integrated method for PCR cleanup and oligonucleotide removal
|
|
EP1529105B1
(en)
|
2002-08-12 |
2012-10-03 |
Société de commercialisation des produits de la recherche appliquée SOCPRA Sciences Santé et Humaines s.e.c. |
Methods to reprogram splice site selection in pre-messenger rnas
|
|
EP1546369A4
(en)
|
2002-08-12 |
2007-01-17 |
Univ Michigan |
DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
|
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
CA2504694C
(en)
|
2002-11-05 |
2013-10-01 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
EP2305812A3
(en)
|
2002-11-14 |
2012-06-06 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
US9045518B2
(en)
|
2002-11-18 |
2015-06-02 |
Santaris Pharma A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
|
US7790867B2
(en)
|
2002-12-05 |
2010-09-07 |
Rosetta Genomics Inc. |
Vaccinia virus-related nucleic acids and microRNA
|
|
WO2004080406A2
(en)
|
2003-03-07 |
2004-09-23 |
Alnylam Pharmaceuticals |
Therapeutic compositions
|
|
CA2524255C
(en)
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
CA2519860C
(en)
|
2003-03-21 |
2018-01-16 |
Santaris Pharma A/S |
Short interfering rna (sirna) analogues
|
|
MXPA05011022A
(es)
|
2003-04-13 |
2006-04-27 |
Enzon Pharmaceuticals Inc |
Profarmacos oligonucleotidos polimericos.
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
US20070009899A1
(en)
|
2003-10-02 |
2007-01-11 |
Mounts William M |
Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
|
|
GB0326578D0
(en)
|
2003-11-14 |
2003-12-17 |
Univ Belfast |
Cancer diagnosis and therapy
|
|
US20050221354A1
(en)
|
2004-02-18 |
2005-10-06 |
Wyeth |
Nucleic acid arrays for monitoring expression profiles of drug target genes
|
|
JP2007534772A
(ja)
|
2004-04-27 |
2007-11-29 |
イルミジェン バイオサイエンシーズ， インコーポレイテッド |
ヒト肝細胞癌細胞を特異的に標的化するための方法および組成物
|
|
CA2566519C
(en)
|
2004-05-14 |
2020-04-21 |
Rosetta Genomics Ltd. |
Micrornas and uses thereof
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
US20070087376A1
(en)
|
2004-08-30 |
2007-04-19 |
Potashkin Judith A |
Splice variants of pre-mRNA transcripts as biomarkers in idiopathic neurodegenerative diseases
|
|
WO2006055786A2
(en)
|
2004-11-19 |
2006-05-26 |
Acadia Pharmaceuticals Inc. |
Methods to identify ligands of hormone nuclear receptors
|
|
US8211864B2
(en)
|
2005-01-26 |
2012-07-03 |
Medical College Of Georgia Research Institute |
Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptors
|
|
US7718625B2
(en)
|
2005-01-27 |
2010-05-18 |
University Of South Florida |
Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof
|
|
US20100150839A1
(en)
|
2005-02-04 |
2010-06-17 |
Massachusetts Institute Of Technology |
Compositions and Methods for Modulating Cognitive Function
|
|
JP5202296B2
(ja)
|
2005-04-01 |
2013-06-05 |
ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド |
肝臓傷害のバイオマーカー
|
|
US20100088778A1
(en)
*
|
2005-06-16 |
2010-04-08 |
John Charles Mulley |
Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
|
|
WO2006133955A1
(en)
|
2005-06-17 |
2006-12-21 |
Baxter International Inc. |
Adamts13-comprising compositions having thrombolytic activity
|
|
SI2548560T1
(sl)
|
2005-06-23 |
2015-12-31 |
Isis Pharmaceuticals, Inc. |
Sestavki in postopki za moduliranje izrezovanja smn2
|
|
EP3611266B1
(en)
|
2005-08-23 |
2022-11-09 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
WO2007028065A2
(en)
|
2005-08-30 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
WO2007047913A2
(en)
|
2005-10-20 |
2007-04-26 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulation of lmna expression
|
|
WO2007048629A2
(en)
|
2005-10-28 |
2007-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modulation of rna silencing efficiency by argonaute proteins
|
|
US20080280848A1
(en)
|
2005-10-28 |
2008-11-13 |
Volker Patzel |
Structures of Active Guide Rna Molecules and Method of Selection
|
|
US20100022495A1
(en)
|
2005-11-01 |
2010-01-28 |
President And Fellows Of Harvard College |
Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
|
|
US20090291437A1
(en)
|
2005-11-02 |
2009-11-26 |
O'brien Sean |
Methods for targeting quadruplex sequences
|
|
US7785834B2
(en)
|
2005-11-10 |
2010-08-31 |
Ercole Biotech, Inc. |
Soluble TNF receptors and their use in treatment of disease
|
|
EP1792981A1
(en)
|
2005-12-02 |
2007-06-06 |
Humboldt-Universität zu Berlin |
Microginin producing proteins and nucleic acids encoding a microginin gene cluster as well as methods for creating microginins
|
|
PT2161038E
(pt)
|
2006-01-26 |
2014-03-10 |
Isis Pharmaceuticals Inc |
Composições e suas utilizações dirigidas à huntingtina
|
|
EP1984499B1
(en)
|
2006-01-27 |
2015-05-27 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
JP5342881B2
(ja)
|
2006-01-27 |
2013-11-13 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
６−修飾された二環式核酸類似体
|
|
US8007790B2
(en)
|
2006-04-03 |
2011-08-30 |
Stowers Institute For Medical Research |
Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
|
|
EP2023940B1
(en)
|
2006-05-05 |
2011-06-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of sglt2
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
AU2007249349B2
(en)
|
2006-05-11 |
2012-03-08 |
Isis Pharmaceuticals, Inc. |
5'-Modified bicyclic nucleic acid analogs
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
CN101460624B
(zh)
|
2006-06-08 |
2013-06-05 |
阿明诺化学株式会社 |
具有iNOS的表达控制作用的正义寡核苷酸以及含有其的组合物
|
|
EP2034018A4
(en)
|
2006-06-27 |
2010-02-10 |
Takeda Pharmaceutical |
GENETICALLY MODIFIED ANIMAL AND ITS USE
|
|
WO2008094194A2
(en)
|
2006-07-24 |
2008-08-07 |
Athena Diagnostics, Inc. |
Pkd mutations and evaluation of same
|
|
WO2008049085A1
(en)
|
2006-10-18 |
2008-04-24 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
|
US20090264353A1
(en)
|
2007-10-19 |
2009-10-22 |
Santaris Pharma A/S |
Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
|
|
ATE551061T1
(de)
|
2006-11-13 |
2012-04-15 |
Santaris Pharma As |
Lna-nukleosid-phosphoramidate
|
|
US8293684B2
(en)
|
2006-11-29 |
2012-10-23 |
Exiqon |
Locked nucleic acid reagents for labelling nucleic acids
|
|
WO2008086807A2
(en)
|
2007-01-19 |
2008-07-24 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
|
EP2114981B1
(en)
|
2007-01-29 |
2013-05-08 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
|
AR065648A1
(es)
|
2007-03-09 |
2009-06-24 |
Pioneer Hi Bred Int |
Identificacion de transportadores de amonio (amts) para la regulacion del metabolismo de nitrogeno en plantas
|
|
WO2008111485A1
(ja)
|
2007-03-09 |
2008-09-18 |
Riken |
モノヌクレオシドまたはモノヌクレオチドから誘導される構造を有する化合物、核酸、標識物質、核酸検出方法およびキット
|
|
WO2008111908A1
(en)
|
2007-03-15 |
2008-09-18 |
Jyoti Chattopadhyaya |
Five- and six-membered conformationally locked 2',4'- carbocyclic ribo-thymidines for the treatment of infections and cancer
|
|
EP2149605B1
(en)
|
2007-03-22 |
2013-07-03 |
Santaris Pharma A/S |
Short RNA antagonist compounds for the modulation of target mRNA
|
|
EP2170917B1
(en)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
EP2173760B2
(en)
|
2007-06-08 |
2015-11-04 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
|
CA2692579C
(en)
|
2007-07-05 |
2016-05-03 |
Isis Pharmaceuticals, Inc. |
6-disubstituted bicyclic nucleic acid analogs
|
|
WO2009023855A2
(en)
|
2007-08-15 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
|
AU2008317566B2
(en)
|
2007-10-26 |
2014-05-01 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
WO2009064920A2
(en)
|
2007-11-13 |
2009-05-22 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
|
US8546556B2
(en)
|
2007-11-21 |
2013-10-01 |
Isis Pharmaceuticals, Inc |
Carbocyclic alpha-L-bicyclic nucleic acid analogs
|
|
WO2009082607A2
(en)
|
2007-12-04 |
2009-07-02 |
Alnylam Pharmaceuticals, Inc. |
Targeting lipids
|
|
US8846386B2
(en)
|
2007-12-18 |
2014-09-30 |
University Of Kentucky Research Foundation |
sVEGFR-2 and its role in lymphangiogenesis modulation
|
|
JP5608863B2
(ja)
|
2007-12-28 |
2014-10-15 |
公立大学法人横浜市立大学 |
新生児期〜乳児期発症の難治性てんかんの検出方法
|
|
WO2009099942A2
(en)
|
2008-01-31 |
2009-08-13 |
Alnylam Pharmaceuticals, Inc. |
Chemically modified oligonucleotides and uses thereof
|
|
WO2009100320A2
(en)
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
|
JP5409658B2
(ja)
|
2008-03-13 |
2014-02-05 |
セレラ コーポレーション |
静脈血栓症に関連した遺伝子多型、その検出方法および使用
|
|
DK2285819T3
(da)
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
|
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
WO2009149921A2
(en)
|
2008-06-11 |
2009-12-17 |
Bionucleon S.R.L. |
Inhibition of hrp-3 using modified oligonucleotides
|
|
EP2151248A1
(en)
|
2008-07-30 |
2010-02-10 |
Johann Bauer |
Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
WO2010036698A1
(en)
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
|
JP2012507989A
(ja)
|
2008-11-07 |
2012-04-05 |
センター ホスピタライヤー ユニヴェルシテール サント−ジュスティーヌ |
Ｓｙｎｇａｐ１機能不全ならびに精神遅滞の診断および治療用途でのその使用
|
|
ES2600781T3
(es)
|
2008-12-04 |
2017-02-10 |
Curna, Inc. |
Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
|
|
WO2010080509A1
(en)
|
2008-12-19 |
2010-07-15 |
Philadelphia Health And Education Corporation |
Compositions and methods for diminishing viral infection and inflammation associated with viral infection
|
|
US20100166784A1
(en)
|
2008-12-30 |
2010-07-01 |
The Washington University |
Method and compositions for modulating th17 cell development
|
|
CA2750379A1
(en)
|
2009-01-14 |
2010-07-22 |
Gordon J. Lutz |
Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
|
|
ES2618572T3
(es)
|
2009-05-08 |
2017-06-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la familia de la distrofina mediante inhibición de un transcrito antisentido natural para la familia de dmd
|
|
PT3305302T
(pt)
|
2009-06-17 |
2018-12-14 |
Biogen Ma Inc |
Composições e métodos de modulação de excisões de smn2 em um sujeito
|
|
EP2275545A1
(en)
|
2009-07-16 |
2011-01-19 |
Julius-Maximilians-Universität Würzburg |
Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis
|
|
EP2462153B1
(en)
|
2009-08-06 |
2015-07-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
US20120252877A1
(en)
|
2009-08-14 |
2012-10-04 |
Theramind Research, Llc |
Methods and compositions for treatment of tuberous sclerosis complex
|
|
EP2475786B1
(en)
|
2009-09-08 |
2016-03-30 |
Laboratory Corporation of America Holdings |
Compositions and methods for diagnosing autism spectrum disorders
|
|
WO2011032034A2
(en)
|
2009-09-10 |
2011-03-17 |
University Of Idaho |
Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids
|
|
AU2010312751B2
(en)
|
2009-10-29 |
2014-07-24 |
Osaka University |
Bridged artificial nucleoside and nucleotide
|
|
LT2499249T
(lt)
|
2009-11-12 |
2018-12-27 |
The University Of Western Australia |
Priešprasmės molekulės ir patologijų gydymo būdai
|
|
WO2011066312A1
(en)
|
2009-11-25 |
2011-06-03 |
Elitech Holding B.V. |
Minor groove binder (mgb)-oligonucleotide mirna antagonists
|
|
WO2011085102A1
(en)
|
2010-01-11 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
WO2011097643A1
(en)
|
2010-02-08 |
2011-08-11 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
WO2011115818A1
(en)
|
2010-03-17 |
2011-09-22 |
Isis Pharmaceuticals, Inc. |
5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2550361B1
(en)
|
2010-03-25 |
2017-02-08 |
The J. David Gladstone Institutes |
Compositions and methods for treating neurological disorders
|
|
WO2011127210A1
(en)
|
2010-04-06 |
2011-10-13 |
Massachusetts Institute Of Technology |
Targeted delivery of nucleic acids
|
|
US20110269735A1
(en)
|
2010-04-19 |
2011-11-03 |
Celera Corporation |
Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
|
|
RU2664452C2
(ru)
|
2010-04-19 |
2018-08-17 |
Нлифе Терапеутикс, С.Л. |
Конъюгат, медицинское средство и способы лечения и/или профилактики депрессии и болезни, связанной с отложением телец Леви
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
US9156873B2
(en)
|
2010-04-28 |
2015-10-13 |
Isis Pharmaceuticals, Inc. |
Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
|
|
EP2571530A4
(en)
|
2010-05-20 |
2014-03-05 |
Univ Rochester |
METHOD AND COMPOSITIONS FOR AUTOPHAGIA MODULATION
|
|
US8957200B2
(en)
|
2010-06-07 |
2015-02-17 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2580228B1
(en)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2582397A4
(en)
|
2010-06-15 |
2014-10-29 |
Isis Pharmaceuticals Inc |
COMPOUNDS AND METHOD FOR MODULATING INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS
|
|
WO2011163499A2
(en)
*
|
2010-06-23 |
2011-12-29 |
Opko Curna, Llc |
Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
|
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
|
WO2012106529A1
(en)
|
2011-02-02 |
2012-08-09 |
The Trustees Of Princeton University |
Jagged1 as a marker and therapeutic target for breast cancer bone metastasis
|
|
US20140128449A1
(en)
|
2011-04-07 |
2014-05-08 |
The Board Of Regents Of The University Of Texas System |
Oligonucleotide modulation of splicing
|
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
US9957558B2
(en)
|
2011-04-28 |
2018-05-01 |
Life Technologies Corporation |
Methods and compositions for multiplex PCR
|
|
DK2718437T3
(en)
|
2011-06-10 |
2018-08-06 |
Inst Nat Sante Rech Med |
Methods for the Treatment of Liver's Congenital Amaurosis
|
|
WO2012178146A1
(en)
|
2011-06-24 |
2012-12-27 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of spinal muscular atrophy
|
|
AU2012284265B2
(en)
|
2011-07-19 |
2017-08-17 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
US8592156B2
(en)
|
2011-08-08 |
2013-11-26 |
Roche Molecular Systems, Inc. |
Predicting response to anti-CD20 therapy in DLBCL patients
|
|
EP3453761A1
(en)
|
2011-08-29 |
2019-03-13 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
BR112014004895B1
(pt)
|
2011-09-05 |
2022-07-05 |
Stichting Radboud Universitair Medisch Centrum |
Oligonucleotídeos antissentido para o tratamento de amaurose congênita de leber
|
|
KR101991980B1
(ko)
|
2011-09-06 |
2019-06-21 |
큐알엔에이, 인크. |
소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
|
|
WO2013043878A2
(en)
|
2011-09-20 |
2013-03-28 |
The George Washington University |
Alternative splicing variants of genes associated with prostate cancer risk and survival
|
|
US20140343127A1
(en)
|
2011-11-11 |
2014-11-20 |
Santaris Pharma A/S a corporation |
Compounds for the modulation of smn2 splicing
|
|
WO2013074814A2
(en)
|
2011-11-15 |
2013-05-23 |
University Of Utah Research Fourdation |
Morpholinos, morpholino upregulating, and associated methods
|
|
CN104053786B
(zh)
|
2011-11-29 |
2017-06-06 |
生命技术公司 |
用于多重pcr的方法和组合物
|
|
US20150025231A1
(en)
|
2012-01-11 |
2015-01-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for modulation of ikbkap splicing
|
|
EP2812342B1
(en)
|
2012-02-08 |
2017-11-15 |
Ionis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
|
EP2812004B1
(en)
|
2012-02-10 |
2018-06-27 |
PTC Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
US8846885B2
(en)
|
2012-02-17 |
2014-09-30 |
Ajinomoto Co., Inc. |
Oligonucleotide with protected base
|
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US20140378526A1
(en)
|
2012-05-11 |
2014-12-25 |
City Of Hope |
Design of nucleic acid binding molecules with non-watson crick and non-canonical pairing based on artificial mutation consensus sequences to counter escape mutations
|
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
EP3536787A1
(en)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
JP6453212B2
(ja)
|
2012-07-13 |
2019-01-16 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
キラル制御
|
|
US8729263B2
(en)
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
US9950001B2
(en)
|
2012-08-20 |
2018-04-24 |
The Regents Of The University Of California |
Polynucleotides having bioreversible groups
|
|
EP2898072A1
(en)
|
2012-09-24 |
2015-07-29 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Restoration of the cftr function by splicing modulation
|
|
WO2014049536A2
(en)
|
2012-09-25 |
2014-04-03 |
Universidade De Lisboa |
Drug targets for cystic fibrosis and other conditions
|
|
WO2014052638A1
(en)
|
2012-09-27 |
2014-04-03 |
Idenix Pharmaceuticals, Inc. |
Esters and malonates of sate prodrugs
|
|
UA116639C2
(uk)
|
2012-10-09 |
2018-04-25 |
Рег'Юлес Терап'Ютікс Інк. |
Способи лікування синдрому альпорта
|
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
WO2014066915A2
(en)
|
2012-10-26 |
2014-05-01 |
Smith Larry J |
Methods and compositions to produce ss-rnai activity with enhanced potency
|
|
JP6542669B2
(ja)
|
2012-10-31 |
2019-07-10 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
癌の治療
|
|
WO2014078749A1
(en)
|
2012-11-15 |
2014-05-22 |
The Regents Of The University Of California |
Splice modulating oligonucleotides that inhibit cancer
|
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
CN103667438B
(zh)
|
2013-01-07 |
2015-04-01 |
赵晨 |
一种筛查HRDs致病突变的方法及涉及的基因芯片杂交探针设计方法
|
|
AU2014206668A1
(en)
|
2013-01-18 |
2015-08-06 |
Anna Mary Rose |
Therapeutics and diagnostics based on minisatellite repeat element 1 (MSR1)
|
|
ES2817050T3
(es)
|
2013-02-04 |
2021-04-06 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido selectivos y usos de los mismos
|
|
EP2957567B1
(en)
|
2013-02-18 |
2019-06-05 |
Shionogi & Co., Ltd. |
Nucleoside and nucleotide, having nitrogen-containing hetercycle structure
|
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
US9549909B2
(en)
|
2013-05-03 |
2017-01-24 |
The Katholieke Universiteit Leuven |
Method for the treatment of dravet syndrome
|
|
WO2014198890A1
(en)
|
2013-06-13 |
2014-12-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
|
|
WO2014201413A1
(en)
|
2013-06-14 |
2014-12-18 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating non-coding rna
|
|
CA2913785C
(en)
|
2013-06-25 |
2021-08-31 |
F. Hoffmann-La Roche Ag |
Compounds for treating spinal muscular atrophy
|
|
EP3033425A4
(en)
|
2013-08-16 |
2017-07-26 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin
|
|
AU2014306416B2
(en)
|
2013-08-16 |
2021-02-25 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating RNA
|
|
EP3033423A4
(en)
|
2013-08-16 |
2017-04-26 |
Rana Therapeutics Inc. |
Epigenetic regulators of frataxin
|
|
JP2016531570A
(ja)
|
2013-08-16 |
2016-10-13 |
ラナ セラピューティクス インコーポレイテッド |
ユークロマチン領域を標的とするオリゴヌクレオチド
|
|
EP3035935B1
(en)
|
2013-08-19 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Compounds for use in the prophylaxis and treatment of cancer
|
|
PL3041958T4
(pl)
|
2013-09-04 |
2020-11-02 |
Cold Spring Harbor Laboratory |
Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi
|
|
JP6618910B2
(ja)
|
2013-09-05 |
2019-12-11 |
サレプタ セラピューティクス，インコーポレイテッド |
酸性α−グルコシダーゼにおけるアンチセンス誘導エクソン２包含
|
|
WO2015036451A1
(en)
|
2013-09-11 |
2015-03-19 |
Synthena Ag |
Nucleic acids and methods for the treatment of pompe disease
|
|
JP6723918B2
(ja)
|
2013-11-21 |
2020-07-15 |
メモリアル スローン ケタリング キャンサー センター |
ヒト多能性幹細胞からの機能的頭蓋プラコード派生体の特定
|
|
US10119168B2
(en)
|
2014-03-12 |
2018-11-06 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of kidney fibrosis
|
|
US20170044540A1
(en)
|
2014-04-22 |
2017-02-16 |
Mina Therapeutics Limited |
Sarna compositions and methods of use
|
|
EP4039807A1
(en)
|
2014-06-10 |
2022-08-10 |
Erasmus University Rotterdam Medical Center |
Antisense oligonucleotides useful in treatment of pompe disease
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
GB201411468D0
(en)
|
2014-06-27 |
2014-08-13 |
Univ Edinburgh |
Novel treatment for endometriosis
|
|
CA2958524A1
(en)
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
|
CN107109411B
(zh)
|
2014-10-03 |
2022-07-01 |
冷泉港实验室 |
核基因输出的定向增加
|
|
US20170224758A1
(en)
|
2014-10-17 |
2017-08-10 |
The Broad Institute, Inc. |
Compositions and methods of treating muscular dystrophy
|
|
JP2017533721A
(ja)
|
2014-11-14 |
2017-11-16 |
アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
タンパク質の調節のための化合物及び方法
|
|
GB201421379D0
(en)
|
2014-12-02 |
2015-01-14 |
Isis Innovation Ltd And Medical Res Council |
Molecule
|
|
US11219634B2
(en)
|
2015-01-21 |
2022-01-11 |
Genevant Sciences Gmbh |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
|
EP3256126B1
(en)
|
2015-02-09 |
2024-03-27 |
F. Hoffmann-La Roche AG |
Compounds for the treatment of cancer
|
|
US9840709B2
(en)
|
2015-02-20 |
2017-12-12 |
Rosalind Franklin University Of Medicine And Science |
Antisense compounds targeting genes associated with cystic fibrosis
|
|
WO2016138534A2
(en)
|
2015-02-27 |
2016-09-01 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
MX2017012426A
(es)
|
2015-04-03 |
2018-01-26 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de tmprss6.
|
|
US10668171B2
(en)
|
2015-05-30 |
2020-06-02 |
Ptc Therapeutics, Inc. |
Methods for modulating RNA splicing
|
|
CA3000660A1
(en)
|
2015-09-24 |
2017-03-30 |
The Trustees Of The University Of Pennsylvania |
Triptycene derivatives for nucleic acid junction stabilization
|
|
EP3359685B1
(en)
|
2015-10-09 |
2026-01-28 |
University Of Southampton |
Modulation of gene expression for deregulated protein expression
|
|
GB2546719B
(en)
|
2015-10-09 |
2021-07-14 |
Univ Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
EP3183347A4
(en)
|
2015-10-17 |
2018-04-18 |
Lifesplice Pharma LLC |
Splice modulating oligonucleotides and methods of use thereof
|
|
CN108348527A
(zh)
|
2015-10-30 |
2018-07-31 |
Ptc医疗公司 |
用于治疗癫痫的方法
|
|
CA3005245A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of alagille syndrome
|
|
EP3390634A4
(en)
|
2015-12-14 |
2019-08-14 |
Cold Spring Harbor Laboratory |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
JP7049249B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
中枢神経系疾患の処置のための組成物および方法
|
|
JP7054675B2
(ja)
|
2015-12-14 |
2022-04-14 |
コールド スプリング ハーバー ラボラトリー |
網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法
|
|
WO2017106375A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of tuberous sclerosis complex
|
|
JP2018538287A
(ja)
|
2015-12-14 |
2018-12-27 |
コールド スプリング ハーバー ラボラトリー |
多発性嚢胞腎の処置のためのアンチセンスオリゴマー
|
|
EP3933041B1
(en)
|
2015-12-14 |
2024-01-31 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant retardation
|
|
CA3005090A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of liver diseases
|
|
EP3390666A4
(en)
|
2015-12-14 |
2019-08-07 |
Cold Spring Harbor Laboratory |
COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
AU2017292173B2
(en)
|
2016-07-06 |
2022-01-13 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
|
US20190218255A1
(en)
|
2016-09-16 |
2019-07-18 |
Olipass Corporation |
Scn9a antisense oligonucleotides
|
|
EA201992358A1
(ru)
|
2017-04-03 |
2020-03-24 |
Инкоудид Терапьютикс, Инк. |
Тканеселективная экспрессия трансгена
|
|
WO2018191482A2
(en)
|
2017-04-13 |
2018-10-18 |
Ovid Therapeutics Inc. |
Methods of treating developmental encephalopathies
|
|
CA3062247A1
(en)
|
2017-05-09 |
2018-11-15 |
Zogenix International Limited |
Methods of treating doose syndrome using fenfluramine
|
|
WO2018213491A1
(en)
|
2017-05-16 |
2018-11-22 |
Praxis Precision Medicines, Inc. |
Methods of treating epilepsy and neurodevelopmental disorders
|
|
SG11202001590RA
(en)
|
2017-08-25 |
2020-03-30 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of conditions and diseases
|
|
GB2610100B
(en)
|
2017-10-23 |
2023-08-16 |
Stoke Therapeutics Inc |
Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases
|
|
IL274926B2
(en)
|
2017-12-01 |
2026-04-01 |
Encoded Therapeutics Inc |
Pyrazolopyrimidines with activity against respiratory syncytial virus
|
|
CA3095125A1
(en)
|
2018-03-27 |
2019-10-03 |
Factor Bioscience Inc. |
Nucleic acid-based therapeutics
|
|
AU2019253700B2
(en)
|
2018-04-09 |
2025-08-14 |
Allen Institute |
Rescuing voltage-gated sodium channel function in inhibitory neurons
|
|
WO2019224864A1
(ja)
|
2018-05-21 |
2019-11-28 |
国立研究開発法人理化学研究所 |
Ｓｃｎ１ａ遺伝子の発現増強法とそれによるドラベ症候群の治療法
|
|
US12259378B2
(en)
|
2018-05-25 |
2025-03-25 |
Praxis Precision Medicines, Inc. |
Dynamic clamps and methods of use thereof
|
|
WO2019236750A2
(en)
|
2018-06-05 |
2019-12-12 |
Tufts Medical Center, Inc. |
Targeted treatment of autism spectrum disorder and other neurological or psychiatric disorders
|
|
MX2020013930A
(es)
|
2018-06-22 |
2021-03-09 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion del canal de sodio dependiente de voltaje alfa subunidad 9 (scn9a).
|
|
EP3815696A4
(en)
|
2018-06-26 |
2022-11-30 |
Nippon Shinyaku Co., Ltd. |
ANTISENSE OLIGONUCLEOTIDE CONTAINING COMPOSITION AND ITS USE IN THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
|
|
BR112021003224A2
(pt)
|
2018-08-20 |
2021-07-20 |
Rogcon, Inc. |
oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a
|
|
US10905778B2
(en)
|
2018-09-26 |
2021-02-02 |
Case Western Reserve University |
Methods and compositions for treating a premature stop codon-mediated disorder
|
|
KR20210134003A
(ko)
|
2019-02-27 |
2021-11-08 |
스톡 테라퓨틱스, 인크. |
병태 및 질환의 치료를 위한 안티센스 올리고머
|
|
BR112022010882A2
(pt)
|
2019-12-06 |
2022-10-04 |
Stoke Therapeutics Inc |
Oligômeros antissenso para tratamento de condições e doenças
|
|
EP4392562A4
(en)
|
2021-08-27 |
2025-09-24 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION
|
|
EP4562020A2
(en)
|
2022-07-29 |
2025-06-04 |
Stoke Therapeutics, Inc. |
Compounds for treatment of conditions and diseases
|
|
EP4665407A2
(en)
|
2023-02-14 |
2025-12-24 |
Stoke Therapeutics, Inc. |
Antisense oligomer formulations
|
|
WO2025024568A1
(en)
|
2023-07-24 |
2025-01-30 |
Stoke Therapeutics, Inc. |
Methods for treating conditions and diseases
|
|
US20250066781A1
(en)
|
2023-07-24 |
2025-02-27 |
Stoke Therapeutics, Inc. |
Methods for treating conditions and diseases
|
|
WO2025199503A1
(en)
|
2024-03-22 |
2025-09-25 |
Stoke Therapeutics, Inc. |
Methods for treating conditions and diseases
|